X4 Pharmaceuticals, Inc (NASDAQ:XFOR)
| Market Cap | 265.04M-15.4% |
| Revenue (ttm) | 15.85M-51.6% |
| Net Income | -90.14M+11.6% |
| EPS | -1.20+92.0% |
| Shares Out | 94.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 434,332 |
| Open | 2.74 |
| Previous Close | 2.77 |
| Day's Range | 2.71 - 2.86 |
| 52-Week Range | 2.70 - 4.83 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 11.50(+309.25%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About XFOR
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$XFOR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in XFOR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by XFOR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
XFOR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
XFOR Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Balance as of June 30, 2026 | $546.00K | 54.38% |
| Beginning balance at December 31, 2025 | $458.00K | 45.62% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New XFOR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to XFOR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in XFOR
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $10.50M |
| IWMiShares Russell 2000 ETF | $5.97M |
| VXFVanguard Extended Market ETF | $4.14M |
| VTWOVanguard Russell 2000 ETF | $1.88M |
| IWCiShares Micro-Cap ETF | $721.96K |
| SBIOALPS Medical Breakthroughs ETF | $351.22K |
Estimated from each fund’s disclosed top holdings × AUM
XFOR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from XFOR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score